A Study of Once-Daily Oral Orforglipron (LY3502970) in Japanese Adult Participants With Obesity Disease
Фаза 3
Завершено
NCT05931380
| Заболевание | Obesity |
|---|
| Фаза | Фаза 3 |
|---|
| Спонсор | Eli Lilly and Company |
|---|
| Статус | Завершено |
|---|
| Участники | 238 участн. |
|---|
| Вмешательство | Orforglipron |
|---|
| Дата начала | 31.07.2023 |
|---|
| Дата завершения | 19.06.2025 |
|---|
| Публикация результатов | 20.07.2026 |
|---|
Кратко
The main purpose of this study is to investigate the efficacy and safety of oral orforglipron in participants with obesity disease with obesity-related health problems.
Percent Change From Baseline in Body Weight at Week 72
Baseline, Week 72 · percent change
| Placebo QD | -0.63 ± 0.732 percent change |
|---|
| 6 mg Orforglipron QD | -5.90 ± 0.866 percent change |
|---|
| 12 mg Orforglipron QD | -8.69 ± 1.136 percent change |
|---|
| 36 mg Orforglipron QD | -7.93 ± 1.063 percent change |
|---|
| p-value | <.001 |
|---|
| LS Mean Difference (Final values) | -5.28 (95% CI -7.52–-3.03) |
|---|
Percentage of Participants Who Achieved With Greater Than or Equal to (≥) 5% Body Weight Reduction From Baseline
Baseline to Week 72 · Percentage of Participants
| Placebo QD | 15.00 Percentage of Participants |
|---|
| 6 mg Orforglipron QD | 45.90 Percentage of Participants |
|---|
| 12 mg Orforglipron QD | 61.40 Percentage of Participants |
|---|
| 36 mg Orforglipron QD | 58.33 Percentage of Participants |
|---|
| p-value | <.001 |
|---|
| Risk Difference (RD) | 30.36 (95% CI 15.09–45.62) |
|---|
Открыть в BENITIONS
Открыть на ClinicalTrials.gov
Другие исследования по этому заболеванию
Все исследования
Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.